Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivonescimab + Chemotherapy in Advanced/Metastatic Gastric and Gastroesophageal Adenocarcinoma
NCT06846346Phase 2Recruiting
- Sponsor
- Unicancer
- Start
- Nov 2025
- Primary completion
- Sep 2027
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ivonescimab in gastric adenocarcinoma, esophageal adenocarcinoma (EAC), sponsored by Unicancer. Started Nov 2025; status: recruiting.
02
Drugs
ivonescimab
03
Conditions
gastric adenocarcinomaesophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on NCT06846346.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06846346.